180 related articles for article (PubMed ID: 16640813)
1. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
Kimby E; Treon SP; Anagnostopoulos A; Dimopoulos M; Garcia-Sanz R; Gertz MA; Johnson S; LeBlond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone M; Bladé J
Clin Lymphoma Myeloma; 2006 Mar; 6(5):380-3. PubMed ID: 16640813
[TBL] [Abstract][Full Text] [Related]
2. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
[TBL] [Abstract][Full Text] [Related]
3. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
4. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
6. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
[TBL] [Abstract][Full Text] [Related]
7. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.
Merlini G; Sarosiek S; Benevolo G; Cao X; Dimopoulos M; Garcia-Sanz R; Gatt ME; Fernandez de Larrea C; San-Miguel J; Treon SP; Minnema MC
Semin Hematol; 2023 Mar; 60(2):113-117. PubMed ID: 37099030
[TBL] [Abstract][Full Text] [Related]
8. Waldenström's macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
10. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.
Treon SP; Tedeschi A; San-Miguel J; Garcia-Sanz R; Anderson KC; Kimby E; Minnema MC; Benevolo G; Qiu L; Yi S; Terpos E; Tam CS; Castillo JJ; Morel P; Dimopoulos M; Owen RG
Semin Hematol; 2023 Mar; 60(2):97-106. PubMed ID: 37173155
[TBL] [Abstract][Full Text] [Related]
11. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
12. A review of Waldenstrom's macroglobulinemia.
McDermott MK; Bell EM
Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
15. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
16. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Bladé J; Montoto S; Rosiñol L; Montserrat E
Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
[TBL] [Abstract][Full Text] [Related]
17. Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
García-Sanz R; Ocio E; Caballero A; Magalhães RJ; Alonso J; López-Anglada L; Villaescusa T; Puig N; Hernández JM; Fernández-Calvo J; Aguilar A; Martín A; López R; Paiva B; Orfao A; Vidriales B; San-Miguel JF; Del Carpio D
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):168-71. PubMed ID: 21856552
[TBL] [Abstract][Full Text] [Related]
18. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871
[TBL] [Abstract][Full Text] [Related]
19. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Ilizaliturri F; Huff CA; Kassim A; Krishnan AY; Medeiros BC; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Tricot G; Weber DM; Yahalom J; Yunus F; Kumar R; Shead DA;
J Natl Compr Canc Netw; 2012 Oct; 10(10):1211-9. PubMed ID: 23054875
[TBL] [Abstract][Full Text] [Related]
20. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM).
Anagnostopoulos A; Giralt S
Bone Marrow Transplant; 2002 Jun; 29(12):943-7. PubMed ID: 12098060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
